Literature DB >> 28790054

Goldilocks Dilemma of Dose Titration in Heart Failure With Reduced Ejection Fraction: Too Little, Too Much, or Just Right?

Larry A Allen1, James C Fang2.   

Abstract

Entities:  

Keywords:  Editorials; angiotensin-converting enzyme inhibitors; comorbidity; dose response; heart failure

Mesh：

Substances：

Year:  2017        PMID： 28790054      PMCID： PMC5568799          DOI： 10.1161/CIRCHEARTFAILURE.117.004406

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  7 in total

1.  Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF.

Authors:  Mihai Gheorghiade; Nancy M Albert; Anne B Curtis; J Thomas Heywood; Mark L McBride; Patches Johnson Inge; Mandeep R Mehra; Christopher M O'Connor; Dwight Reynolds; Mary Norine Walsh; Clyde W Yancy; Gregg C Fonarow
Journal:  Congest Heart Fail       Date:  2011-09-19

2.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

3.  Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators.

Authors: 
Journal:  Eur Heart J       Date:  1998-03       Impact factor: 29.983

4.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

Authors:  M Packer; P A Poole-Wilson; P W Armstrong; J G Cleland; J D Horowitz; B M Massie; L Rydén; K Thygesen; B F Uretsky
Journal:  Circulation       Date:  1999-12-07       Impact factor: 29.690

5.  Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.

Authors:  Muhammad Shahzeb Khan; Gregg C Fonarow; Ali Ahmed; Stephen J Greene; Muthiah Vaduganathan; Hassan Khan; Catherine Marti; Mihai Gheorghiade; Javed Butler
Journal:  Circ Heart Fail       Date:  2017-08       Impact factor: 8.790

6.  Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

Authors:  Marvin A Konstam; James D Neaton; Kenneth Dickstein; Helmut Drexler; Michel Komajda; Felipe A Martinez; Gunter A J Riegger; William Malbecq; Ronald D Smith; Soneil Guptha; Philip A Poole-Wilson
Journal:  Lancet       Date:  2009-11-16       Impact factor: 79.321

7.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245
  7 in total
  1 in total

1.  Trends in Frailty and Use of Evidence-Based Pharmacotherapy for Heart Failure in Australian Hospitalised Patients: An Observational Study.

Authors:  Yogesh Sharma; Chris Horwood; Paul Hakendorf; Campbell Thompson
Journal:  J Clin Med       Date:  2021-12-10       Impact factor: 4.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.